

Aims: An epidemiological study of dengue Virus and Surveillance Outbreak in Dimapur, Northeast India.

Epibeni N Humtsoe

Submitted: 20-06-2023

Accepted: 29-06-2023

ABSTRACT: Across the world, dengue fever has emerged as a major health concern. It is a seasonal and is caused by the bite of *Aedes mosquito* found in swampy areas, and water logging. Infection with the dengue virus has a very complicated and dynamic epidemiology. From August 2022 to January 2023, a thorough epidemiological survey was carried out in Dimapur. The first outbreak was recorded in urban area Dimapur, Nagaland. In this study, serum samples were collected from IPD, OPD and other source from private Hospital and Laboratories to detect the presence of IgM ELISA in patients with positive dengue NS1 antigen and IgG/IgM antibodies of RAT.

Key: Complement System, Dengue, *Aedes aegypti*, *Aedes albopictus*.

I. INTRODUCTION:

The flavivirus-driven disease dengue spreads the fastest among mosquito-borne illnesses. In 1946 [1], there were possibly the first reports of it in India. Around the world, it is a widespread vector-borne disease. It breeds in man-made containers and is a major vector [2]. The disease is spread by mosquitoes. The flavivirus that causes the serotypes of dengue virus (DEN 1, 2, 3, and 4) has the highest rate of dissemination. [3- 7]. In nearly all of India's states, dengue is the most prevalent sickness that necessitates hospitalisation. Although reports are currently coming from both urban and rural areas [8], the National Vector Borne Disease Control Programme (NVBDCP), the Integrated Disease Surveillance Programme (IDSP), and other organisations work together in a network of 52 Virus Research and Diagnostic Laboratories (VRDL) to monitor dengue fever. This network was set up by the Department of Health Research.

The proliferation of the dengue virus infection is significantly impacted by weather variables such as temperature, rainfall, and other variables. Rash, nausea, vomiting, sore throat, and a sudden onset of a high-grade fever are some of the signs and symptoms of dengue fever (DF). [6- 7] Hypovolemic shock, also referred to as Dengue Shock Syndrome (DSS), is the cause of circulatory

collapse in DF [3]. In an immunosuppressed person, a primary infection frequently leads to DF. [5,9]

The goal of the current study was to determine the seroprevalence of dengue virus infection in Nagaland by identifying IgG, IgM, and NS1 antibodies against the virus in all clinically suspected cases of dengue infection, depending on whether the fever lasted longer than or less than 5 days at the time of presentation in an outpatient and inpatient department of a tertiary care hospital.

II. THE IMMUNE SYSTEM'S CELLS

DENV is thought to enter the bloodstream when mosquitoes feed on people, infecting young Langerhans cells (epidermal dendritic cells [DC] (10,11) and keratinocytes). Infected cells go from the infection site to the lymph nodes, where they attract monocytes and macrophages, which serve as the infection's targets. Blood-derived monocytes (12), myeloid DC (13), splenic and hepatic macrophages (14-15), and other mononuclear cells are all infected. According to the virus virulence hypothesis, nucleotide differences DENV strains are assumed to be responsible for more severe sickness. DENV serotypes can be further subdivided into different genotypes, and changes in viral genetics are connected to virulence (16,17).

When defending against infections, the hemostatic system and complement system work closely together. It is a key humoral element of innate immunity. The host can fully initiate the more slowly emerging adaptive immunity with the aid of innate immune systems. When plasma leakage might be found, high plasma levels of the activation products C3a and C5a are evaluated (18-20). Complement activation is essential for understanding the pathophysiology of dengue. (21). An important part of NS1's function in complement activation has been hypothesised. Additionally, the NS1 produced by infected cells has the power to instantly activate complement components that are present in the fluid phase (22).

III. STRUCTURE AND NON-STRUCTURE PROTEINS:

The DENV's shape revealed that its surface was icosahedra and flat. The genome codes for three structural proteins: a capsid (C, 100 amino acids), a premembrane/membrane (PrM/M, 75 amino acids), and an envelope (E, 495 amino acids). Seven non-structural (NS) proteins are also present: NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5. Proteins with the N word include structural proteins. Non-structural proteins are responsible for virus replication, whereas structural proteins support the assembly of the DENV virion's constituent parts. [23]

Protein (E) Envelope:

The viral envelope glycoprotein allows the virus to enter the target cell through viral endocytosis, which is mediated by clathrin. The virus enters the cell and a cross-bridge connects it to the host [24-25]. The primary role of the E protein is to bind to and associate with the host cell membrane. DENV cannot assault early stages of infection because of the E protein inhibitors. Each monomer is made up of numerous domains, including the stem domain, soluble ectodomain, and C-terminal transmembrane anchor domain.

Membrane protein/PrM (M) :

The PrM/M protein is composed of 175 amino acids, two transmembrane helices, an N-terminal region, and a M domain. The prM protein is broken down by a cellular protease, which also preserves 180 copies of the 75 residues of the core protein while releasing 91 amino acids at the N-terminus [26]. The N and M domains of the Golgi apparatus break, resulting in the conversion of PrM into M-protein and the maturation of the virus [27].

Capsid Protein (C):

This homodimeric protein has 100 amino acids, four α -helical regions, an unorganised N-terminal domain, and a molecular mass of 12 kDa [27,29-31]. The interaction of the positively charged N-terminal domain with negatively charged lipid droplets is a step in the formation of viral particles [32]. The C protein is essential for the formation of nucleocapsids in the initial stages of dengue virion assembly. It is a favourable target for vaccines and antivirals because of the lack of an adverse drug-enhancing response (ADE), and it is also required for prM maturation [33-37,28].

IV. MATERIALS & METHODS

This epidemiological study was carried out at the District Hospital Dimapur sentinel monitoring unit over a 6-month period, from August 2022 to January 2023. The study comprised patients with clinic histories of fever. The present symptoms and demographic characteristics were noted. The standard laboratory tests that were run between 2 to 5 day served as the foundation for this investigation using patient serum.

Serology and Processing

Blood was obtained from patients with a history and duration of fever who had clinical suspicion of dengue viral infection on the day they reported to the hospital. The separated serum samples were then tested using serology for the illness. NS1 antigen and IgG/IgM antibody detection using the qualitative membrane-based immunoassay known as the Dengue Combo NS1 Ag and IgG/IgM Ab Rapid Test requires sample preparation. NS1 Ag and IgG/IgM Ab Rapid test positive samples were transferred to the sentinel monitoring unit for confirmation using an IgM ELISA. Private hospitals, clinics, and labs sent positive samples to the sentinel monitoring unit for confirmation after getting informed consent.

V. CLINICAL FEATURES

Every dengue patient had a history of fever, and other symptoms included myalgia, headache, nausea, vomiting, itching, abdominal pain, rash, and bleeding from the mouth and nose. Swampy areas and water logging, which are spread by mosquito bites, are the outbreak's sources.

VI. RESULT

The current study was carried out during a 6-month period, from August 2022 to January 2023, at the District Hospital in Dimapur, Nagaland. In this investigation, a serum sample from 705 samples was used to confirm the presence of IgM ELISA in patients with positive dengue NS1 antigen and IgG/IgM antibodies of RAT. 151 were positive, while 554 were negative. 77 female and 74 male respondents were among the 151 who tested positive. The most frequently impacted age group was that of 15 to 45 years old with 63percentages. There were noticeable differences in the incidence of infection, according to the study's distribution of dengue cases between the monsoon and post-monsoon seasons. The pre-monsoon season, which ran from January to June, saw no favorable examples. The maximum occurrences occurred between September and

December of previous year during the post-monsoon period. Males were less likely to get an infection than females were. 97 instances were from urban Dimapur, with 52 male and 45 female, 44

from rural Dimapur, with 18 male and 26 female, and 10 from other districts in Nagaland, with 4 male and 6 female.

Table 1.1 Dengue cases analysis from Aug 2022 to Jan 2023 in Dimapur Nagaland

Gender wise breakup of all cases detected

Row Labels	September	October	November	December	Grand Total
F	11	25	29	12	77
M	8	21	33	12	74
Grand Total	19	46	62	24	151

Table 1.2 Infection Month Wise

Row Labels	Count of Month	Age Wise Breakup	positive	Percentage
September	19	0-4 yrs	1	1%
October	46	5 - 14 yrs	13	9%
November	62	15-45 yrs	89	63%
December	24	46-60 yrs	24	17%
Grand Total	151	60 above	14	10%
			141	100%

Table 1.3 Urban -rural breakup

Row Labels	Count of Name of the Patient
others	10
rural	44
Urban	96
Urban	1
Grand Total	151

Gender Wise breakup only for Dimapur District

Gender	Cases	percentage
Male	70	49.65%
Female	71	50.35%
Total	141	100.00%

Total tested 705

total Positive 151

Positivity 21.42%

Table 2.1 Travel History

Count of Name of the Patient	Column Labels	others	rural	Urban	Urban	Grand Total
Row Labels						
No		8	43	96	1	148

Yes	2	1		3
Grand Total	10	44	96	151

VII. CONCLUSIONS:

The current study documents a dengue outbreak that occurred in Nagaland from August 2022 to January 2023. In contrast to IgM antibodies, it was shown that the majority of dengue cases were identified in patient sera by the presence of viral NS1 antigen. Consequently, it is understood that NS1 test early detection of Dengue cases aids in diagnostic detection and case confirmation. With NS1 assays that are noticeably more sensitive for primary than secondary Dengue infection, viral antigen identification is especially helpful during the first five days of sickness. Fever was the most prevalent presenting symptom in clinical presentations of Dengue-positive. The distribution of dengue cases between the monsoon and post-monsoon seasons revealed observable variations in the prevalence of infection. Males had a lower infection risk than females did. Epidemiologists conducted surveys in the area during the outbreak, which confirmed the presence of mosquito populations there. Swamps, waterlogging, and mosquito bites from *Aedes (Stegomyia) aegypti* and *Aedes (Stegomyia) albopictus* were all identified as potential causes of infection.

REFERENCE:

- [1]. Karamchandani PV. Dengue group of fevers in India. *Lancet* 1946;247(6386):92-3.
- [2]. Sunyoto Temmy, Bhatia Rajesh, Dash Aditya P. Changing epidemiology of dengue in South-East Asia. *WHO South East Asia J Public Health* 2013;2(1):23, doi:http://dx.doi.org/10.1186/1475-2875-2-23.
- [3]. Gubler DJ, Reiter P, Ebi KL, Yap W, Nasci R, et al. (2001) Climate Variability and Change in the United States: Potential Impacts on Vector- and Rodent-borne Diseases. *Environmental Health Perspectives Supplements* 109: 223.
- [4]. Lipp EK, Huq A, Colwell RR (2002) Effects of global climate on infectious disease: the cholera model. *Clinical Microbiology Reviews* 15: 757-770.
- [5]. Wu P-C, Guo H-R, Lung S-C, Lin C-Y, Su H-J (2007) Weather as an effective
- [6]. Rigau-Perez J, Clark G, Gubler D, Reiter P, Sanders E, et al. (1998) Dengue and Dengue haemorrhagic fever. *The Lancet* 352: 971-977. doi:10.1016/S0140-6736(98)03151-1
- [7]. Gupta Ekta, Ballani Neha. Current perspectives on the spread of dengue in India. *Infect Drug Resist* 2014;7:337-42, doi:http://dx.doi.org/10.2147/IDR.S55376
- [8]. Department of Health Research, Govt of India. Establishment of a network of Laboratories for managing epidemics and Natural Calamities (VRDL) <http://dhr.gov.in/schemes/establishment-networklaboratories-managing-epid>
- [9]. Kakkar M. Dengue fever is massively under-reported in India, hampering our response. *BMJ*. 2012 Dec 19; 345:e8574-e8574. <https://doi.org/10.1136/bmj.e8574> PMID: 23255584
- [10]. Limon-Flores, A. Y., M. Perez-Tapia, I. Estrada-Garcia, G. Vaughan, A. Escobar-Gutierrez, J. Calderon-Amador, S. E. Herrera-Rodriguez, A. Brizuela-Garcia, M. Heras-Chavarria, A. Flores-Langarica, L. Cedillo-Barron, and L. Flores-Romo. 2005. Dengue virus inoculation to human skin explants: an effective approach to assess in situ the early infection and the effects on cutaneous dendritic cells. *Int. J. Exp. Pathol.* 86:323-334. [PMC free article] [PubMed] [Google Scholar]
- [11]. Wu, S. J., G. Grouard-Vogel, W. Sun, J. R. Mascola, E. Brachtel, R. Putvatana, M. K. Louder, L. Filgueira, M. A. Marovich, H. K. Wong, A. Blauvelt, G. S. Murphy, M. L. Robb, B. L. Innes, D. L. Bix, C. G. Hayes, and S. S. Frankel. 2000. Human skin Langerhans cells are targets of dengue virus infection. *Nat. Med.* 6:816-820. [PubMed] [Google Scholar]
- [12]. Durbin, A. P., M. J. Vargas, K. Wanionek, S. N. Hammond, A. Gordon, C. Rocha, A. Balmaseda, and E. Harris. 2008. Phenotyping of peripheral blood mononuclear cells during acute dengue illness demonstrates infection and increased activation of monocytes in

- severe cases compared to classic dengue fever. *Virology* 376:429-435. [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]
- [14]. Butthep, P., S. Chunhakan, K. Tangnaratchakit, S. Yoksan, K. Pattanapanyasat, and A. Chuansumrit. 2006. Elevated soluble thrombomodulin in the febrile stage related to patients at risk for dengue shock syndrome. *Pediatr. Infect. Dis. J.* 25:894-897. [[PubMed](#)] [[Google Scholar](#)]
- [15]. Ho, L. J., M. F. Shaio, D. M. Chang, C. L. Liao, and J. H. Lai. 2004. Infection of human dendritic cells by dengue virus activates and primes T cells towards Th0-like phenotype producing both Th1 and Th2 cytokines. *Immunol. Investig.* 33:423-437. [[PubMed](#)] [[Google Scholar](#)]
- [16]. Ho, L. J., J. J. Wang, M. F. Shaio, C. L. Kao, D. M. Chang, S. W. Han, and J. H. Lai. 2001. Infection of human dendritic cells by dengue virus causes cell maturation and cytokine production. *J. Immunol.* 166:1499-1506. [[PubMed](#)] [[Google Scholar](#)]
- [17]. Kwan, W. H., A. M. Helt, C. Maranon, J. B. Barbaroux, A. Hosmalin, E. Harris, W. H. Fridman, and C. G. Mueller. 2005. Dendritic cell precursors are permissive to dengue virus and human immunodeficiency virus infection. *J. Virol.* 79:7291-7299. [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]
- [18]. Libraty, D. H., S. Pichyangkul, C. Ajariyakhajorn, T. P. Endy, and F. A. Ennis. 2001. Human dendritic cells are activated by dengue virus infection: enhancement by gamma interferon and implications for disease pathogenesis. *J. Virol.* 75:3501-3508. [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]
- [19]. Blackley, S., Z. Kou, H. Chen, M. Quinn, R. C. Rose, J. J. Schlesinger, M. Coppage, and X. Jin. 2007. Primary human splenic macrophages, but not T or B cells, are the principal target cells for dengue virus infection in vitro. *J. Virol.* 81:13325-13334. [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]
- [20]. de la C Sierra, B., G. Garcia, A. B. Perez, L. Morier, M. Alvarez, G. Kouri, and M. G. Guzman. 2006. Ethnicity and difference in dengue virus-specific memory T cell responses in Cuban individuals. *Viral Immunol.* 19:662-668. [[PubMed](#)] [[Google Scholar](#)]
- [21]. Jessie, K., M. Y. Fong, S. Devi, S. K. Lam, and K. T. Wong. 2004. Localization of dengue virus in naturally infected human tissues, by immunohistochemistry and in situ hybridization. *J. Infect. Dis.* 189:1411-1418. [[PubMed](#)] [[Google Scholar](#)]
- [22]. Kou, Z., M. Quinn, H. Chen, W. W. Rodrigo, R. C. Rose, J. J. Schlesinger, and X. Jin. 2008. Monocytes, but not T or B cells, are the principal target cells for dengue virus (DV) infection among human peripheral blood mononuclear cells. *J. Med. Virol.* 80:134-146. [[PubMed](#)] [[Google Scholar](#)]
- [23]. Marchette, N. J., S. B. Halstead, W. A. Falkler, Jr., A. Stenhouse, and D. Nash. 1973. Studies on the pathogenesis of dengue infection in monkeys. 3. Sequential distribution of virus in primary and heterologous infections. *J. Infect. Dis.* 128:23-30. [[PubMed](#)] [[Google Scholar](#)]
- [24]. Leitmeyer, K. C., D. W. Vaughn, D. M. Watts, R. Salas, I. Villalobos, C. de, C. Ramos, and R. Rico-Hesse. 1999. Dengue virus structural differences that correlate with pathogenesis. *J. Virol.* 73:4738-4747. [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]
- [25]. Sanchez, I. J., and B. H. Ruiz. 1996. A single nucleotide change in the E protein gene of dengue virus 2 Mexican strain affects neurovirulence in mice. *J. Gen. Virol.* 77:2541-2545. [[PubMed](#)] [[Google Scholar](#)]
- [26]. Ubol, S., T. Chareonsirisuthigul, J. Kasisith, and C. Klungthong. 2008. Clinical isolates of dengue virus with distinctive susceptibility to nitric oxide radical induce differential gene responses in THP-1 cells. *Virology* 376:290-296. [[PubMed](#)] [[Google Scholar](#)]
- [27]. Churboonchart, V., N. Bhamarapravati, and P. Futrakul. 1983. Crossed immunoelectrophoresis for the detection of split products of the third complement in dengue hemorrhagic fever. I. Observations in patients' plasma. *Am. J. Trop. Med. Hyg.* 32:569-576. [[PubMed](#)] [[Google Scholar](#)]

- [28]. Nishioka, K. 1974. Serum complement level in dengue hemorrhagic fever. *Allerg. Immunol. (Leipz)* 21:385-392. [PubMed] [Google Scholar]
- [29]. Pujar, G.V.; Sethu, A.K.; Bhagyalalitha, M.; Singh, M. Dengue structural proteins as antiviral drug targets: Current status in the drug discovery & development. *Eur. J. Med. Chem.* 2021, 221, 113527.
- [30]. Ubol, S., P. Masrinoul, J. Chaijaruwanich, S. Kalayanaroj, T. Charoensirisuthikul, and J. Kasisith. 2008. Differences in global gene expression in peripheral blood mononuclear cells indicate a significant role of the innate responses in progression of dengue fever but not dengue hemorrhagic fever. *J. Infect. Dis.* 197:1459-1467. [PubMed] [Google Scholar]
- [31]. Kurosu, T., P. Chaichana, M. Yamate, S. Anantapreecha, and K. Ikuta. 2007. Secreted complement regulatory protein clusterin interacts with dengue virus nonstructural protein 1. *Biochem. Biophys. Res. Commun.* 362:1051-1056. [PubMed] [Google Scholar]
- [32]. Perera, R.; Kuhn, R.J. Structural proteomics of dengue virus. *Curr. Opin. Microbiol.* 2008, 11, 369-377. [CrossRef]
- [33]. Behnam, M.A.M.; Nitsche, C.; Boldescu, V.; Klein, C.D. The medicinal chemistry of dengue virus. *J. Med. Chem.* 2016, 59,5622-5649. [CrossRef]
- [34]. Alen, M.M.F.; Schols, D. Dengue virus entry as target for antiviral therapy. *J. Trop. Med.* 2012, 2012, 628475. [CrossRef]
- [35]. Nasar, S.; Rashid, N.; Iftikhar, S. Dengue proteins with their role in pathogenesis, and strategies for developing an effective anti-dengue treatment: A review. *J. Med. Virol.* 2020, 92, 941-955. [CrossRef]
- [36]. Keelapang, P.; Sriburi, R.; Supasa, S.; Panyadee, N.; Songjaeng, A.; Jairungsri, A.; Puttikhunt, C.; Kasinrerak, W.; Malasit, P.; Sittisombut, N. Alterations of pr-M cleavage and virus export in pr-M junction chimeric dengue viruses. *J. Virol.* 2004, 78,2367-2381. [CrossRef] [PubMed]
- [37]. Byk, L.A.; Gamarnik, A.V. Properties and functions of the dengue virus capsid protein. *Annu. Rev. Virol.* 2016, 3, 263-281. [CrossRef] [PubMed]
- [38]. Perera, R.; Kuhn, R.J. Structural proteomics of dengue virus. *Curr. Opin. Microbiol.* 2008, 11, 369-377. [CrossRef]